BioLineRx Ltd. reported impressive 2024 financial results highlighting strategic partnerships and enhanced focus on oncology and rare diseases.

BioLineRx has updated investors on its Q2 2026 performance and ongoing clinical trials, emphasizing progress in anti-cancer therapy GLIX1.

Reported Friday, Sep 25 - 4:33pm EDT (TheFly subscription required to read more.)

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types  PR Newswire

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology co...

BioLineRx and Hemispherian are set to present promising preclinical results for their cancer treatment GLIX1 at the EANO 2026 conference in Rome.

The Investor Relations website contains information about BioLineRx's business for stockholders, potential investors, and financial analysts.

Reported Monday, Aug 31 - 7:08am EDT (TheFly subscription required to read more.)

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data showing GLIX1 achieved potent antitumor activity in TMZ-resistant patient-derived xenograft (PDX) GBM in vivo model - -...

The Investor Relations website contains information about BioLineRx's business for stockholders, potential investors, and financial analysts.

BioLineRx has secured $3.75 million through a registered direct offering and concurrent private placement aimed at advancing its oncological therapies.

TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive...

Reported Friday, Aug 28 - 8:02am EDT (TheFly subscription required to read more.)

BioLineRx (NASDAQ: BLRX) announced a definitive agreement to sell an aggregate of 1,348,921 ADSs (or ADS equivalents) at $2.78 per ADS in a registered direct offering, plus accompanying warrants via a concurrent private placement to purchase up to 2,023,382 ADSs at an exercise price of $2.78.The warrants will expire five years from issuance. Gross proceeds are expected to be $3.75 million before fees and expenses, with closing anticipated on or about August 31, 2026, subject to customary conditions. BioLineRx intends to use net proceeds for research and development, working capital and general corporate purposes.In connection with the offering, BioLineRx agreed to amend outstanding warrants held by the investor to purchase 277,273 ADSs, reducing the exercise price to $2.78 and extending the expiration to August 31, 2031.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudite...

Financial results are unaudited for the quarter ended June 30; CEO Philip Serlin will give remarks at 8:30 a.m. EDT, with a webcast and replay online.

Discover how BioLineRx and Hemispherian AS's innovative research on GLIX1 combined with PARP inhibitors targets ovarian cancer at ESMO 2026.

TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel...